Craig CM, et al. – Aim of this current study was to evaluate the adequacy, pharmacokinetics and tolerability of subcutaneous (SC) Ex–9 in patients with post–bariatric hypoglycemia (PBH). It was showed that SC Ex–9 appears to represent a safe, effective, and targeted therapeutic approach for treatment of PBH. Future study involving multiple doses with chronic dosing is warranted.